These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28326244)

  • 21. Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Morozumi K; Sato M; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
    Metabolites; 2020 Dec; 11(1):. PubMed ID: 33374949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib: the antiangiogenic effects and beyond.
    Hao Z; Sadek I
    Onco Targets Ther; 2016; 9():5495-505. PubMed ID: 27660467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
    Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
    Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
    FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.
    Abdel-Aziz AK; Abdel-Naim AB; Shouman S; Minucci S; Elgendy M
    Front Pharmacol; 2017; 8():718. PubMed ID: 29066973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
    Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
    J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
    Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
    J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
    Boorjian S
    Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.
    Aimudula A; Nasier H; Yang Y; Zhang R; Lu P; Hao J; Bao Y
    Int J Clin Exp Pathol; 2018; 11(5):2389-2400. PubMed ID: 31938351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.
    Gao H; Deng L
    Cell Biochem Biophys; 2014 Mar; 68(2):419-25. PubMed ID: 23975598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.
    Li JR; Yang CK; Wang SS; Chen CS; Chiu KY; Cheng CL; Yang CR; Ho HC; Ko JL; Ou YC
    Anticancer Res; 2014 Oct; 34(10):5643-7. PubMed ID: 25275068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.